Skip to main content

UGA Wins $832K Award from NIH for Purchase of Orbitrap Elite

Premium

This story originally ran on Oct. 11.

By Adam Bonislawski

The University of Georgia has won an $832,030 High-End Instrumentation award from the National Institutes of Health with which it plans to purchase a Thermo Scientific Orbitrap Elite mass spectrometer.

The machine will be part of the university's Proteomic and Mass Spectrometry core facility and is intended as an "all-around instrument" for "a variety of bottom-up and top-down [proteomic] analyses," Jon Amster, head of UGA's chemistry department and principal investigator on the grant, told ProteoMonitor.

Amster's group applied for the grant in 2009, intending to purchase an LTQ Orbitrap, but by the time the award was made, Thermo Fisher had released the Orbitrap Elite, and so the researchers opted for the newer machine, he said.

"This instrument is going to serve the whole campus, so we wanted something that would meet the needs of a pretty broad spectrum of researchers," Amster said, added that he believes the Elite will be well-suited to both bottom-up and intact protein work.

"We also considered some [time-of-flight] instruments, since they have pretty high mass accuracy now," he said. "But this instrument just seemed a lot more flexible because it has the linear ion trap on the front end, which you can use to do very fast, low-resolution scans, and then when you find something you want to measure at high resolution you can pass it on" to the Orbitrap.

"It also has the capability to do high energy collisional dissociation as well as in-trap dissociation and electron transfer dissociation," he added. "So it was a much more universal instrument."

In addition to the Orbitrap Elite, the UGA facility includes an Applied Biosystems 4700 Proteomics Analyzer and a Bruker Autoflex MALDI-TOF machine.


Have topics you'd like to see covered in ProteoMonitor? Contact the editor at abonislawski [at] genomeweb [.] com.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.